Cero Therapeutics Reports $5.9 Million Net Loss and Faces Funding Challenges in Q1 2026

Cero Therapeutics Holdings, Inc. reported a net loss of $5.9 million for the first quarter of 2026, an increase of 15.3% compared to a net loss of $5.1 million in the same period of 2025. The company's total operating expenses decreased slightly to $4.8 million from $4.9 million year-over-year, primarily due to a reduction in research and development (R&D) expenses, which fell to $2.3 million from $2.9 million. This decline in R&D spending reflects decreased clinical activity as the company prepared for and initiated clinical trials for its lead compound, CER-1236, which is currently in Phase 1/1b trials for acute myeloid leukemia (AML).

Cero's financial position showed a significant decline in cash and cash equivalents, which dropped to approximately $857,489 as of March 31, 2026, down from $1.7 million at the end of 2025. The company also reported a working capital deficit of about $9.8 million and an accumulated deficit of approximately $96.7 million. During the quarter, Cero raised $1.5 million through the issuance of convertible notes and $456,166 from the sale of common stock under an equity line of credit (ELOC). However, the company emphasized the need for additional funding to sustain operations and continue its R&D activities.

In terms of operational developments, Cero Therapeutics has made strides in its clinical programs, including receiving FDA clearance for its Investigational New Drug application for CER-1236 in November 2024. The company has dosed multiple patients in its ongoing clinical trials, which is a critical step toward potential commercialization. However, the company has not yet generated any revenue and does not expect to do so in the near term, as it focuses on advancing its product candidates through clinical development.

Looking ahead, Cero Therapeutics faces significant challenges, including the need for substantial additional capital to fund its operations and R&D efforts. The company has indicated that it may need to delay or reduce its planned activities if it cannot secure the necessary funding. Furthermore, the company’s common stock is now traded on the OTCQB market following its delisting from Nasdaq, which may impact its ability to raise capital in the future. The management has expressed concerns about the company's ability to continue as a going concern within the next year, highlighting the urgency of securing additional financing to support its ongoing operations and development initiatives.